Home › NDC Lookup › RxCUI directory › RxCUI 2100010

Baloxavir marboxil 40 MG Oral Tablet [Xofluza] — RxCUI 2100010

RxNorm drug concept · Semantic branded drug
RxCUI 2100010 Semantic branded drug · SBD ● Current RxNorm concept 5 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2100010
Official nameBaloxavir marboxil 40 MG Oral Tablet [Xofluza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asXofluza 40 MG Oral Tablet
FDA products mapped5
Package NDCs mapped7
Reported Medicaid activity (SDUD)18,342 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Baloxavir Marboxil: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes — Xofluza is designed as a single-dose treatment. Because baloxavir stays active in your body for a long time (it has a half-life of about 79 hours), one dose is enough to do i...
  • Does Xofluza really work with just one dose?
  • You can take Xofluza with or without food, but there's one important catch: avoid dairy products, calcium-fortified juices or drinks, and any supplements or antacids containing cal...
  • Most people do very well with Xofluza. The most common side effects reported in adults and teens were diarrhea, nausea, headache, bronchitis, and sinusitis — and these were actuall...
📖 Read our full Baloxavir Marboxil guide →

🕸️ Concept Web — How Baloxavir marboxil 40 MG Oral Tablet [Xofluza] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Baloxavir marboxil 40 MG Oral Tablet [Xofluza] RxCUI 2100010

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Baloxavir marboxil 2099995
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xofluza 2100001
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Baloxavir marboxil Oral Tablet 2099999
    • Baloxavir marboxil Oral Product 2099997
    • Baloxavir marboxil Pill 2099998
    • Baloxavir marboxil Oral Tablet [Xofluza] 2100003
    • Xofluza Oral Product 2100004
    • Xofluza Pill 2100005
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

    • {2 (baloxavir marboxil 40 MG Oral Tablet [Xofluza]) } Pack [Xofluza 80 MG Dose Pack (2 x 40 MG Tablets)] 2100100
    • {2 (baloxavir marboxil 40 MG Oral Tablet) } Pack 2100026

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Baloxavir marboxil 40 MG Oral Tablet SCD · 2100008
  • Baloxavir marboxil 40 MG SCDC · 2100007
  • Baloxavir marboxil Oral Tablet SCDF · 2099999
  • Baloxavir marboxil Oral Product SCDG · 2099997
  • Baloxavir marboxil Pill SCDG · 2099998
  • {2 (baloxavir marboxil 40 MG Oral Tablet) } Pack GPCK · 2100026

Brand-Name Concepts

  • Baloxavir marboxil 40 MG [Xofluza] SBDC · 2100009
  • Baloxavir marboxil Oral Tablet [Xofluza] SBDF · 2100003
  • Xofluza Oral Product SBDG · 2100004
  • Xofluza Pill SBDG · 2100005
  • Xofluza BN · 2100001
  • {2 (baloxavir marboxil 40 MG Oral Tablet [Xofluza]) } Pack [Xofluza 80 MG Dose Pack (2 x 40 MG Tablets)] BPCK · 2100100

📦 FDA Products & Package NDCs

5 products · 7 package NDCs
7 package NDCs map to RxCUI 2100010 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50242-0583-01 1 BOTTLE, GLASS in 1 CARTON (50242-583-01) / 20 mL in 1 BOT... Xofluza Genentech, Inc. 2020-11-23
50242-0599-01 1 PACKET in 1 CARTON (50242-599-01) / 1 GRANULE, FOR SUSPEN... Xofluza Genentech, Inc. 2025-05-30
50242-0617-01 1 PACKET in 1 CARTON (50242-617-01) / 1 GRANULE, FOR SUSPEN... Xofluza Genentech, Inc. 2025-05-30
50242-0860-01 1 BLISTER PACK in 1 CARTON (50242-860-01) / 1 TABLET, FILM... Xofluza Genentech, Inc. 2021-03-26
50242-0860-86 1 BLISTER PACK in 1 CARTON (50242-860-86) / 1 TABLET, FILM... Xofluza Genentech, Inc. 2021-08-31
50242-0877-01 1 BLISTER PACK in 1 CARTON (50242-877-01) / 1 TABLET, FILM... Xofluza Genentech, Inc. 2021-03-26
50242-0877-86 1 BLISTER PACK in 1 CARTON (50242-877-86) / 1 TABLET, FILM... Xofluza Genentech, Inc. 2021-08-31
Observed labelers: Genentech, Inc. (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.